Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 410 alone and in combination in KRAS-altered advanced or metastatic solid tumors
NL-OMON59115Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of AMG 410 in Nonhematologic neoplasms (2 arms), sponsored by Amgen. Started Dec 2025; status: recruiting.
02
Drugs
AMG 410
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59115.